Open research · Psilocybin & psilocin

Countries and organisations

Explore psilocybin trials by country, sponsor and research facility. Compare registry status, study-start trends, conditions and mapped research sites.

Free access · No subscription for research tools or data exports

Explore registry geography and organisations

Trial, condition or NCT IDCountrySponsorPhaseStatusConditionReset

2 trials match this view; 1 mapped facilities. Latest indexed registry check Oct 9, 2026 01:24 UTC. Country membership uses reported locations, including locations without coordinates; Mapped-facility counts cover all sites of matching trials, including international sites, and require valid coordinates.

Enrollment sum: 34 across 2 records with a reported count. Planned and actual counts are mixed; this is not a count of unique treated participants.

Export filtered registry facts · JSONInteractive world map Germany source-checked report

Recorded study-start years

202222

Current indexed registry status

Active, not recruiting22

Reported research conditions

Healthy11

Bipolar II Disorder11

Counts describe indexed registry records, not efficacy or total research activity. A trial can count under several conditions or countries. Unknown dates are excluded from the start-year chart; future years reflect planned starts. Stopped studies may reflect recruitment, funding or strategy and are not automatically treatment failures.

Matching trial records

2 matching registry records. Dates are registry milestones, not promised results announcements.
Trial	Sponsor and phase	Status	Enrollment	Start / primary completion / completion	Research workflow
Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy Adults NCT05317689 Healthy	University of California, San Francisco PHASE1	Active, not recruiting Registry updated 2025-06-10	20 ESTIMATED	2022-05-26 2025-01-16 2025-07
An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder NCT05065294 Bipolar II Disorder	University of California, San Francisco PHASE2	Active, not recruiting Registry updated 2024-09-25	14 ESTIMATED	2022-01-28 2024-08-01 2025-07

Reported research facilities

University of California, San FranciscoSan Francisco, California, United States

This list includes mapped sites of matching trials, including international sites; locations without usable coordinates are omitted. Facilities are registry-reported trial sites, not an independently verified clinic or research-centre directory. Current services and contact details must be checked at the source.